Thus, effective methods of treatment include combining immunotherapy with targeting PD1+ TAMs and tumor-derived exosomal HMGB1 to resuscitate immune function in individuals suffering from ESCC. The gene discussed is HMGB1; the disease is esophageal squamous cell carcinoma.